Your browser doesn't support javascript.
loading
Low complement levels are related to poor obstetric outcomes in women with obstetric antiphospholipid syndrome. The EUROAPS Registry Study Group.
Esteve-Valverde, Enrique; Alijotas-Reig, Jaume; Belizna, Cristina; Marques-Soares, Joana; Anunciacion-Llunell, Ariadna; Feijóo-Massó, Carlos; Sáez-Comet, Luis; Mekinian, Arsene; Ferrer-Oliveras, Raquel; Lefkou, Elmina; Morales-Pérez, Stephanie; Hoxha, Ariel; Tincani, Angela; Nalli, Cecilia; Pardos-Gea, Josep; Marozio, Luca; Maina, Aldo; Espinosa, Gerard; Cervera, Ricard; De Carolis, Sara; Latino, Omar; Udry, Sebastian; Llurba, Elisa; Garrido-Gimenez, Carmen; Trespidi, Laura; Gerosa, Maria; Chighizola, Cecilia B; Rovere-Querini, Patrizia; Canti, Valentina; Mayer-Pickel, Karoline; Tabacco, Sara; Arnau, Anna; Miró-Mur, Francesc.
Afiliação
  • Esteve-Valverde E; Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Parc Taulí, Sabadell, Spain. Electronic address: Eesteve@tauli.cat.
  • Alijotas-Reig J; Systemic Autoimmune Diseases Research Unit, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall D'Hebron University Hospital, Barcelona, Spain; Department of Medicine, Faculty of Medicine, Universitat Autònoma de Barcelo
  • Belizna C; Vascular and Coagulation Department, University Hospital Angers and CNRS, 6015, INSERM 1083 Unit, Angers, France.
  • Marques-Soares J; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Anunciacion-Llunell A; Systemic Autoimmune Diseases Research Unit, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
  • Feijóo-Massó C; Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Parc Taulí, Sabadell, Spain.
  • Sáez-Comet L; Internal Medicine Department, Miguel Servet University Hospital, Zaragoza, Spain.
  • Mekinian A; AP-HP, Hôpital Saint-Antoine, Service de Médecine Interne and Inflammation- Immunopathology-Biotherapy Department (DHU I2B), Sorbonne Universités, UPMC Univ, Paris, France.
  • Ferrer-Oliveras R; Obstetrics and Gynaecology Department, Hospital Quirón, Barcelona, Spain.
  • Lefkou E; Haematology Unit, Hippokration Hospital of Thessaloniki, Thessaloniki, Greece.
  • Morales-Pérez S; Internal Medicine Department, Althaia Healthcare University Network of Manresa, Systemic Autoimmune Disease Unit, Manresa, Barcelona, Spain.
  • Hoxha A; Rheumatology Unit, Department of Medicine-DIMED, University of Padua, Padua, Italy.
  • Tincani A; Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Nalli C; Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
  • Pardos-Gea J; Systemic Autoimmune Diseases Research Unit, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain; Systemic Autoimmune Disease Unit, Department of Internal Medicine, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Marozio L; Department of Obstetrics and Gynaecology, Università di Torino, Torino, Italy.
  • Maina A; Department of Internal Medicine, AO Città della Salute e della Scienza di Torino, Turin, Italy.
  • Espinosa G; Department of Autoimmune Diseases, Hospital Clinic, Institut de Recerca Biomèdica August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • Cervera R; Department of Autoimmune Diseases, Hospital Clinic, Institut de Recerca Biomèdica August Pi I Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
  • De Carolis S; UOC di Patologia Ostetrica, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Latino O; Autoimmune, Thrombophilic Diseases and Pregnancy Division, Dr Carlos G. Durand Hospital, Buenos Aires, Argentina.
  • Udry S; Autoimmune, Thrombophilic Diseases and Pregnancy Division, Dr Carlos G. Durand Hospital, Buenos Aires, Argentina.
  • Llurba E; Obstetrics and Gynaecology Department, High Risk Unit, University Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Garrido-Gimenez C; Obstetrics and Gynaecology Department, High Risk Unit, University Hospital de La Santa Creu I Sant Pau, Barcelona, Spain.
  • Trespidi L; Obstetrics and Gynaecology Department, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.
  • Gerosa M; Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Chighizola CB; Division of Rheumatology, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
  • Rovere-Querini P; Pregnancy and Rheumatic Diseases Clinic Unit of Medicine and Clinical Immunology IRCCS Ospedale San Raffaele Università Vita-Salute San Raffaele, Milan, Italy.
  • Canti V; Pregnancy and Rheumatic Diseases Clinic Unit of Medicine and Clinical Immunology IRCCS Ospedale San Raffaele Università Vita-Salute San Raffaele, Milan, Italy.
  • Mayer-Pickel K; Department of Obstetrics, Medical University Graz, Graz, Austria.
  • Tabacco S; Department of Gynecology Obstetrics and Urology, Sapienza, University of Rome, Rome, Italy.
  • Arnau A; Research and Innovation Unit, Althaia Xarxa Assistencial Universitaria de Manresa, Manresa, Spain.
  • Miró-Mur F; Systemic Autoimmune Diseases Research Unit, Vall D'Hebron Institut de Recerca (VHIR), Barcelona, Spain.
Placenta ; 136: 29-34, 2023 05.
Article em En | MEDLINE | ID: mdl-37028222
ABSTRACT

INTRODUCTION:

Obstetric antiphospholipid syndrome (OAPS) is an autoimmune disease related to antiphospholipid antibodies (aPL) with primaryinflammatory injury followed by clot cascade activation and thrombus formation. Complement system activation and their participation in aPL-related thrombosis is unclosed.

METHODS:

We haveanalysed adverse pregnancy outcomes (APO) related to low complement (LC) levels in a cohort of 1048 women fulfilling classification criteria for OAPS.

RESULTS:

Overall, 223 (21.3%) women presented LC values, during pregnancy. The length of pregnancy was shorter in OAPS women with LC compared to those with normal complement (NC) (median 33 weeks, interquartile range [24-38] vs. 35 weeks [27-38]; p = 0.022). Life new-born incidence was higher in patients with NC levels than in those with LC levels (74.4% vs. 67.7%; p = 0.045). Foetal losses were more related to women with triple or double aPL positivity carrying LC than NC values (16.3% vs. 8.0% NC; p = 0.027). Finally, some placental vasculopathies were affected in OAPS patients with LC as late Foetal Growth Restriction (FGR >34 weeks) rise to 7.2% in women with LC vs. 3.2% with NC (p = 0.007).

DISCUSSION:

Data from our registry indicate that incidence of APO was higher in OAPS women with LC levels and some could be reverted by the correct treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Síndrome Antifosfolipídica Limite: Female / Humans / Male / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações na Gravidez / Síndrome Antifosfolipídica Limite: Female / Humans / Male / Pregnancy Idioma: En Ano de publicação: 2023 Tipo de documento: Article